$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Hematology
Hematology
地拉罗司分散片是否纳入医保?
2025-10-19 11:44:20
Check Details
地拉罗司分散片一盒多少钱?
2025-10-19 11:44:20
Check Details
地拉罗司分散片图片及介绍
2025-10-19 11:44:20
Check Details
地拉罗司分散片怎么吃?
2025-10-19 11:44:20
Check Details
地拉罗司分散片哪里买的到?
2025-10-19 11:44:20
Check Details
地拉罗司分散片是什么药?
2025-10-19 11:44:20
Check Details
地拉罗司分散片一个疗程多少钱?
2025-10-19 11:44:20
Check Details
地拉罗司分散片功效与作用
2025-10-19 11:44:20
Check Details
地拉罗司分散片吃完多长时间见效?
2025-10-19 11:44:20
Check Details
地拉罗司分散片适应症
2025-10-19 11:44:20
Check Details
地拉罗司吃多久为一疗程
2025-10-19 11:44:20
Check Details
地拉罗司分散片是否纳入医保?地拉罗司进医保后多少钱?
2025-10-19 11:44:20
Check Details
1
2
...
48
49
50
51
52
53
54
...
938
939
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
In-Depth Analysis of Selinexor (Xpovio): A Novel Nuclear Export Blockade Option for Relapsed/Refractory Multiple Myeloma and Latest Clinical Advances
2
Acalabrutinib BTK Covalent Inhibition: CLL/SLL Signaling Blockade, Non-Selective Effects, and Progression Monitoring
3
Bosutinib for Ph+ CML: Eligible Populations, Food-Dependent Dosing, Diarrhea and Hepatotoxicity Monitoring
4
Venetoclax BCL-2 Inhibitor: CLL/SLL and AML Ramp-Up, Tumor Lysis Prevention, and Selected Overseas Combination Updates
5
First-Line Pirtobrutinib Without 17p Deletion in CLL/SLL: Noncovalent BTK vs BR, Median PFS Not Reached, HR 0.20
6
Belumosudil for cGVHD: 200mg with Food, Pregnancy Contraception, Liver Monitoring, Drug Interactions
7
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
8
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
9
Acalabrutinib Dosing and Combination Regimens: CLL/SLL, MCL, Safety Adjustments
10
Bosutinib for Ph+ CML: Indications, Dosing Adjustments, and Hepatic/Renal Safety
11
AZA+VEN+IVO Triplet Therapy for Newly Diagnosed IDH1 AML: High Response Rates and Durable Efficacy
12
Anagrelide and Myelofibrosis Risk: Controversy and Monitoring in ET Treatment